232 results about "Hematology" patented technology

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

Provided herein are compositions and methods for treating cancer, e.g., hematological cancer, by administering a CD22 CAR-expressing cell described herein according to a regimen described herein. Also disclosed are methods of making and compositions comprising the same.

The invention belongs to the technical field of data processing, and particularly discloses a method and system for predicting the lifetime of a non-small cell lung cancer patient after radiotherapy, and the method comprises the steps: collecting multi-time-point imaging and hematology follow-up visit data of the patient after radiotherapy, building a longitudinal follow-up visit sequence, and mapping the longitudinal follow-up visit sequence to a unified time axis; determining a bimodal first-time significant improvement point through preset rule judgment, and constructing and standardizing an asynchronous index according to the bimodal first-time significant improvement point; then inputting a feature vector at a follow-up time point, encoding a bimodal sequence through a Transform time sequence encoder, and generating joint representation through cross-modal interaction; and finally, inputting the standardized asynchronous index, the joint representation and the clinical and radiotherapy characteristics into a DeepHit model, and outputting a patient survival distribution prediction result. According to the method, bimodal indexes can be accurately captured, time dislocation is improved, prediction accuracy and individualization degree are improved, and a reliable basis is provided for clinical prognosis evaluation.

The utility model relates to the technical field of hematology department nursing, in particular to a haemostat for hematology department nursing, which comprises a connecting box, arc-shaped plates are fixedly connected to two sides of the connecting box, elastic bands are fixedly connected to the bottoms of the arc-shaped plates, and an arc-shaped block is arranged below the connecting box. Two elastic bands are arranged on limbs in a sleeving mode, a rotary knob is rotated to drive a rectangular rod to move rightwards through rotation of a screw, the rectangular rod drives a triangular block to move to extrude a ball, the ball drives a rectangular plate to move downwards through a cylinder to compress a plurality of springs, and a round rod drives a vertical rod to move downwards through a transverse rod; a vertical rod drives a hemostatic pad to move downwards through an arc-shaped block to conduct continuous pressing hemostasis work on a bleeding point, a second hook-and-loop fastener is held to be separated from a first hook-and-loop fastener, and therefore the hemostatic pad can be taken down to be replaced, pressing work can be continuously conducted on the bleeding point, manual pressing hemostasis is not needed, time and labor are saved, and the fatigue strength of a patient is reduced; meanwhile, the psychological stress of the patient is also reduced.

The invention discloses application of compound fresh bamboo juice in a young group cough model, and relates to the field of medicines.The application comprises the following steps that S1, a cough model is constructed by adopting young beagles, and whether the cough model is successfully constructed or not is verified through behavioral observation, hematological analysis, CT examination and alveolar lavage analysis of the young beagles; and S2, evaluating the efficacy and safety of the successfully constructed young beagle by using a compound fresh bamboo juice. According to the invention, a technical system for evaluating the efficacy of the compound fresh bamboo juice in the cough model of the young beagle is established by taking the young beagle as a research object. In a puppy beagle model, the compound fresh bamboo juice shows good safety, and the medicine remarkably improves target symptoms. The results provide powerful support for the potential curative effect of the compound fresh bamboo juice in children.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

According to the method, by combining hematology indexes and demographic characteristics, five machine learning model performances are constructed and compared, SHAP analysis is carried out through an interpretable model with the optimal performance, key characteristics with the first ten importance degrees are screened out, the five machine learning models are reconstructed by using the key characteristics, the optimal model is selected for SHAP value analysis, and the SHAP value analysis result is obtained. The invention provides an efficient, accurate and transparent AS early auxiliary diagnosis and screening method which has a wide clinical application prospect.

Provided herein are red blood cell control compositions comprising one or more populations of lysable hydrogel particles having an impedance that is substantially similar to the impedance of a human red blood cell of average diameter; and a population of hemoglobin molecules or a population of dye molecules that have substantially similar absorbance as hemoglobin; wherein (i) and / or (ii) are present in an amount that corresponds to a normal blood sample or disease state, or (i) and (ii) are present at a ratio that corresponds to a normal blood sample or disease state.

This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The invention relates to a hematological marker for early diagnosis of novel coronavirus infection in a COVID-19 virus infected person. The invention discloses ROC analysis results of RAR, CRP, LMR, CLR, NAR, CAR and RDW-CV in evaluation of novel coronavirus infection diseases. Wherein the maximum AUC value of the RAR is 0.769, and the minimum AUC value of the RDW-CV is 0.488; the AUC values of CRP, LMR, CLR, NAR and CAR are respectively 0.603, 0.556, 0.591, 0.538 and 0.631, and the AUC values of CRP, LMR, CLR, NAR and CAR are respectively 0.603, 0.556, in addition, the critical value of the RAR is 0.154, and under the critical value, the sensitivity of the RAR is 76.8%, the specificity is 65.3%, and the negative predictive value NPV is 91.7%.

Thereto a method and a system for planning radiation therapy are provided, as well as an arrangement for radiation therapy planning and a computer program product for carrying out the method. For planning the radiation therapy, the following steps are performed. Patient data of a subject to be treated is received as well as image data of the subject to be treated. The image data comprises anatomical image data of one or more organs at risk associated with the functioning of the immune system. Next, the patient 122 data and the image data are processed to obtain a risk score for the one or more organs at risk associated with the functioning of the immune system. The risk score is indicative of the risk of hematologic toxicity in the subject to be treated in response to the radiation therapy. Then the radiation therapy treatment is planned using the obtained risk score.

The invention relates to the technical field of medical instruments, and particularly discloses a regulation and control type hematology department blood transfusion auxiliary device which comprises a lifting plate and a base, a protection frame is fixedly installed at the top of the lifting plate, a bottom plate is arranged at the top of the lifting plate, a connecting frame is fixedly installed at the top of the bottom plate, and the connecting frame is fixedly connected with the lifting plate. Notches are formed in the two sides of the top of the connecting frame, lead screws are rotatably connected to the inner walls of the two notches, the lead screws penetrate through moving blocks and are in threaded connection with the moving blocks, the moving blocks are slidably connected with the notches, and rotating plates are rotatably connected to the moving blocks. And the blood bag clamped by the device can be heated, overturned and shaken, so that the heating efficiency of blood in the blood bag is improved.

The invention relates to the technical field of medical instruments, in particular to a hematology department bone marrow collecting device which comprises a thick tube part and a thin tube part connected to the bottom of the thick tube part, a needle tube is connected in the thin tube part in a sleeved mode and extends downwards, the hematology department bone marrow collecting device further comprises a thick tube part and a thin tube part connected to the bottom of the thick tube part, and the needle tube penetrates through the thin tube part in a sliding mode. The device further comprises a collecting mechanism and a negative pressure adjusting mechanism. The collecting mechanism comprises a button arranged on the top of the thick tube part and a piston abutting against the top of the needle tube. The negative pressure adjusting mechanism is arranged between the button and the piston and is used for adjusting the speed and the flow rate of bone marrow collection; the speed and flow of bone marrow collection can be adjusted, the stability is good, the comfort degree is high, and pain caused by multiple times of puncture to a patient is avoided.

The invention provides a blood transfusion device, method and system for controlling the blood transfusion dosage in the perioperative period, and relates to the technical field of hematology. The blood transfusion device comprises a blood containing module used for containing blood needing to be injected into the body of a patient in the perioperative period; a display module is arranged on the blood containing module and used for displaying state data of blood in the blood containing module in real time; the state data are blood activity indexes and donor information data; the blood injection module is used for obtaining blood from the blood containing module and injecting the blood into the body of the patient; and the blood injection control module is used for controlling the operation of the blood injection module. According to the blood transfusion device, blood transfusion parameters can be accurately controlled, the blood transfusion efficiency and the resource utilization rate are improved, and the blood transfusion risk in the perioperative period is effectively reduced.

Methods and systems for detecting cancer and / or determining a cancer tissue of origin are disclosed. In some embodiments, a multiclass cancer classifier is disclosed that is trained with a plurality of biological samples containing cfDNA fragments. The analytics system derives a feature vector for each sample, and the multiclass classifier predicts a probability likelihood for each of a plurality of tissue of origin (TOO) classes. In some embodiments, the plurality of TOO classes include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples having high tissue signal are pruned from the training sample set. In another embodiment, the analytics system stratifies samples according to tissue signal and applies binary threshold cutoffs determined for each stratum.

The invention discloses a construction method of a leukemia patient hematopoietic stem cell transplantation concurrent oral mucositis risk prediction model, which comprises the following steps: estimating a sample size by adopting an EPV principle, and collecting enough acute leukemia patients for hematopoietic stem cell transplantation treatment cases, basic information, clinical symptoms, hematology indexes and outcome indexes including cases are collected, data arrangement and statistical analysis are carried out by using SAS9.4, risk factors are obtained, and Plt; and the risk factor variable of 0.05 is incorporated into a multi-factor Cox regression model, a risk prediction model is constructed, and visualization is realized. Through verification, the model is stable. The data source of the model has the characteristics of being easy to obtain, objective in index and small in influence on patients, and the model is more suitable for clinical first-line medical staff to monitor oral mucositis.

The present application relates to a kind of aerosol delivery system toxicology scoring method and storage medium, method includes: setting target group, the test biological of target group is in aerosol exposure environment;Blood physiological index and multi-omics data of control group are obtained, the test biological of control group is in air exposure environment;Blood physiological index of target group is measured, and first toxicology score is determined according to the difference of blood physiological index of target group and control group;Multi-omics data of target group is measured, and second toxicology score is determined according to the difference of multi-omics data of target group and control group;According to first toxicology score and second toxicology score, determine the comprehensive toxicology score of target group;Blood physiological index includes blood biochemistry, coagulation function and hematology index;Multi-omics data includes transcriptomics, proteomics and metabolomics data.The present application is evaluated from macroscopic physiological level and microscopic molecular level by the above setting, the toxicological effect of aerosol such as electronic cigarette liquid etc. is evaluated comprehensively.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

The present disclosure relates to 4'-thio-nucleotides and nucleoside compounds for the treatment of various cancers, such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative tumors and plasma cell neoplasms (myeloma). The abstract is intended to be a scanning tool for the purpose of searching in a specific field and is not intended to limit the present invention.

This invention describes CD33 antibodies and their antigen-binding fragments, as well as CD33 / vδ2 multispecific antibodies or their antigen-binding fragments. The invention also describes polynucleotides encoding these antibodies, compositions comprising these antibodies, methods for producing these antibodies, and methods for treating or preventing diseases such as hematological cancers using these antibodies.

A method for the diagnosis of diseases, in particular hematological malignancies or solid tumors, in a subject comprises the steps of isolating (21,61) an extracellular vesicle pellet (3a,3b) obtained from a sample (2) of a biological fluid previously taken from the subject; measuring (31,41,51-52), from said pellet, parameters representative of the six biomarkers (I) size, (II) total amount of the extracellular vesicles, (III) amount of the extra- cellular vesicles expressing on their own surface (III) a first antigen and (IV) a first and a second antigen, (V) mean fluorescence intensity for each of said antigens and (VI) nucleic acid content of the extracellular vesicles; performing a first comparison of the biomarker-representative parameters with respective cut-off values; assigning a partial score to each parameter or to the six biomarkers on the basis of the above first comparison step; calculating a final score, i.e. a subject score, as the sum of the partial scores; performing a second comparison of the final score with at least one predetermined diagnostic threshold value, preferably with two diagnostic upper and lower values; estimating the probability diagnosis of said pathology on the basis of the above second comparison step. The combination of the six biomarkers, in the context of personalized medicine, overcomes the prior art method limitations due to the high clinical heterogeneity between subjects, in terms of sensitivity, with reference to a given pathology, for one rather than the other biomarkers and their relative parameters selected from the six.

The invention relates to a staining reagent for carrying out histological and / or hematological stainings, comprising A) at least one solvent in a proportion of 55% by volume to 99.95% by volume, selected from the group consisting of A1) esters of the formula R1-C(=O)-O-R2, A2) ethers of the formula R3-O-R4, A3) sulfoxides of the formula R5-S(=O)-R6, A4) sulfones of the formula R7-S(=O)2-R8, A5) monohydric alcohols in which the alcoholic OH group is bonded to an aliphatic C atom in a hydrocarbon group of 4 to 8 carbon atoms, A6) diols which have 2 OH groups on an aliphatic hydrocarbon radical with 3 to 6 carbon atoms, A7) formals of the formula R9-O-CH2-O-R10, A8) dihydrolevoglucosenone, A9) propylene carbonate, and A10) N-butylpyrrolidone; B) at least one staining pigment in a proportion of 0.05% by volume to 7% by volume; and C) optionally an additional solvent selected from the group consisting of dimethyl sulfoxide, water, monohydric alcohols with 1 to 3 carbon atoms, and sugar alcohols, wherein R1 represents a C4 to C8 alkyl group or a group of the formula R2-O-C(=O)-R-; R2 represents a C1 to C4 alkyl group; R represents a C2 to C6 alkylene group; R3 represents a C2 to C4 alkyl group which can have an OH group; R4 represents a group of the formula -R11-(O-R12-)n-R13; R11 represents a C2 to C4 alkylene group; R12 represents a C1 to C4 alkylene group; R13 represents H, OH or -O-C(=O)-CH3; n represents 0, 1, 2 or 3; and R5 and R6 independently of one another represent a C1 to C4 alkyl group, with the proviso that the sum of the number of carbon atoms in R5 and R6 is 3 or higher, R7 and R8 independently of one another represent a C1 to C4 alkyl group, and R9 and R10 independently of one another represent a C4 to C8 alkyl group.

The invention relates to the field of medical instruments, in particular to a blood collection auxiliary device for the department of hematology, which comprises a bottom plate and an arch-shaped electric drive guide rail, the bottom plate is a bearing carrier of the auxiliary device, the arch-shaped electric drive guide rail is fixedly mounted on the bottom plate, and the upper part of the arch-shaped electric drive guide rail is a downwards sunken arch-shaped guide rail; the blood sampling device further comprises a blood sampling cylinder, the blood sampling cylinder is rotationally installed in the arch-shaped electric drive guide rail in an electric drive mode, at least two finger through grooves are formed in the outer edge of a cylinder body of the blood sampling cylinder in the circumferential direction at intervals, and electric sliding rail frames are symmetrically and fixedly installed on the left side and the right side of the arch-shaped electric drive guide rail. The adsorption assembly is arranged in the blood sampling cylinder, the negative pressure cylinder and the vacuum pump are used for forming a negative pressure environment, the finger pulp skin of a blood sampling person is tightly adsorbed to a blood sampling opening, the pain feeling when a needle is punctured is reduced, meanwhile, the whole blood sampling process is completed in a closed environment, and the fear and tension feeling of the blood sampling person can be relieved.